UPDATED GUIDELINE SHOWS EVIDENCE-BASED RATIONALE FOR IPF TREATMENT

Aug 5, 2015, 08:51 AM
announcement_icn_45

Antacid Therapy, Nintedanib and Pirfenidone Receive Conditional Recommendation for Patients with IPF – PFF Disease Education Webinar scheduled


The Pulmonary Fibrosis Foundation (PFF) is pleased to recognize the recent release of an update of the 2011 the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. The updated Guideline provides an evidence-based rationale for specific treatments for patients with idiopathic pulmonary fibrosis (IPF).

“The updated Guideline provides a consistent framework for patients and their physicians to discuss different therapeutic options for the treatment of their disease,” said Gregory P. Cosgrove, MD, PFF Chief Medical Officer. “The multidisciplinary panel from the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and the Latin American Thoracic Association should be commended on their tremendous and meticulous efforts to systematically assess and then recommend treatments for patients with IPF based on the available scientific evidence.”

On August 19, 2015, the PFF will present a Disease Education Webinar, “What Does the new IPF Guideline Mean for Patients and Caregivers?”, which will include medical experts reviewing the Guideline as well as answering questions from registered webinar participants. “This is the first time that a patient participated in the development of IPF guidelines,” said David J. Lederer, MD, MS, PFF Senior Medical Advisor, Education and Awareness. “This Guideline contains important recommendations, informed by both physicians and patients, about the role of both new and old treatments for IPF.”

Registration and additional information regarding the webinar is available on the PFF website.
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >